BOUL — Boule Diagnostics AB Share Price
0.000.00%
Last trade - 00:00- SEK316.76m
- SEK489.17m
- SEK558.46m
- 34
- 45
- 48
- 34
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 9.51 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.61 | ||
| Price to Tang. Book | 3.27 | ||
| Price to Free Cashflow | 8.41 | ||
| Price to Sales | 0.57 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -137.46% | ||
| Return on Equity | -88.34% | ||
| Operating Margin | -62.62% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 400.46 | 463.34 | 548.09 | 571.33 | 558.46 | 555 | 595 | 2.28% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | -45.39 | +41.87 | n/a | n/a | +135 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Boule Diagnostics AB is a Sweden-based company engaged in the provision of medical diagnostic and testing equipment. The Company specializes in the development, manufacture and sale of complete blood count (CBC) systems in the field of hematology. It provides reagents, cleaning products and blood calibrators and controls that are used in human and veterinarian laboratories, as well as analyzers and complementing accessories for hematology systems. The Company’s product portfolio comprises five brands: Clinical Diagnostic Solutions, Exigo, Medonic, Swelab and Quintus. The Company’s primary customer base comprises small and medium-sized hospitals, clinics, diagnostics firms and laboratories. Furthermore, It operates worldwide through a number of subsidiaries, such as Boule Medical AB, Boule Nordic AB, Clinical Diagnostic Solutions Inc and Boule Medical (Beijing) Co Ltd.
Directors
- Peter Von Ehrenheim NEC (66)
- Jesper Soderqvist PRE (55)
- Christina Rubenhag CFO
- Bob Ariano SVP
- Mikael Ekholm SVP
- Debbie Herrera SVP
- Eduardo Pagani SVP
- Helena Boerjesson CTO
- Kiarash Farr OTH
- Karin Dahllof IND (62)
- Thomas Eklund IND (54)
- Charlotta Falvin IND (55)
- Jon Risfelt IND (60)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 25th, 1996
- Public Since
- June 23rd, 2011
- No. of Employees
- 226
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 38,833,104
- Address
- Domnarsvgatan 4, SPANGA, 163 53
- Web
- https://www.boule.com/
- Phone
- +46 87447700
- Auditors
- PricewaterhouseCoopers AB
Upcoming Events for BOUL
Q2 2025 Boule Diagnostics AB Earnings Release
Q3 2025 Boule Diagnostics AB Earnings Release
Similar to BOUL
Acarix AB
OMX Nordic Exchange Stockholm
AddLife AB
OMX Nordic Exchange Stockholm
ADDvise AB (publ)
OMX Nordic Exchange Stockholm
ADDvise AB (publ)
OMX Nordic Exchange Stockholm
Arcoma AB
OMX Nordic Exchange Stockholm
FAQ
What is the Boule Diagnostics AB share price?
As of Today at 19:39 UTC, shares in Boule Diagnostics AB are trading at SEK8.16. This share price information is delayed by 15 minutes.
How has the Boule Diagnostics AB share price performed this year?
Shares in Boule Diagnostics AB last closed at SEK8.16 and the price had moved by -13.41% over the past 365 days. In terms of relative price strength the Boule Diagnostics AB share price has underperformed the FTSE Global All Cap Index by -15.58% over the past year.
What are the analyst and broker recommendations for Boule Diagnostics AB?
The overall consensus recommendation for Boule Diagnostics AB is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Boule Diagnostics AB dividend yield?
Boule Diagnostics AB does not currently pay a dividend.
Does Boule Diagnostics AB pay a dividend?
Boule Diagnostics AB does not currently pay a dividend.
When does Boule Diagnostics AB next pay dividends?
Boule Diagnostics AB does not currently pay a dividend.
How do I buy Boule Diagnostics AB shares?
To buy shares in Boule Diagnostics AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Boule Diagnostics AB?
As of the previous close price of SEK8.16, shares in Boule Diagnostics AB had a market capitalisation of SEK316.76m.
Where are Boule Diagnostics AB shares listed?
Here are the trading details for Boule Diagnostics AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: BOUL
What kind of share is Boule Diagnostics AB?
Based on an overall assessment of its quality, value and momentum Boule Diagnostics AB is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Boule Diagnostics AB share price forecast for 2025?
The analyst consensus target price for shares in Boule Diagnostics AB is SEK87.00. That is 966.57% above the last closing price of SEK8.16.
Analysts covering Boule Diagnostics AB currently have a consensus Earnings Per Share (EPS) forecast of SEK0.60 for the next financial year.
Find out moreWhat is the trend in the Boule Diagnostics AB share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Boule Diagnostics AB. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +9.2%.
As of the last closing price of SEK8.16, shares in Boule Diagnostics AB were trading -4.79% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Boule Diagnostics AB PE Ratio?
The Boule Diagnostics AB PE ratio based on its reported earnings over the past 12 months is 9.51. The shares last closed at SEK8.16.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Boule Diagnostics AB?
Boule Diagnostics AB's management team is headed by:
- Peter Von Ehrenheim - NEC
- Jesper Soderqvist - PRE
- Christina Rubenhag - CFO
- Bob Ariano - SVP
- Mikael Ekholm - SVP
- Debbie Herrera - SVP
- Eduardo Pagani - SVP
- Helena Boerjesson - CTO
- Kiarash Farr - OTH
- Karin Dahllof - IND
- Thomas Eklund - IND
- Charlotta Falvin - IND
- Jon Risfelt - IND